GREY:ICOTF - Post by User
Comment by
allain250on Jul 09, 2018 1:40pm
![](https://assets.stockhouse.com/kentico-cms/0340-00/images/Sprite.svg#id_Post_Views_Icon)
42 Views
Post# 28288635
RE:RE:RE:RE:RE:RE:RE:This imnp news
RE:RE:RE:RE:RE:RE:RE:This imnp news“This is an extremely important milestone for the bertilimumab program, as we have secured clinical manufacturing not only for our planned pivotal phase 2/3 trial in bullous pemphigoid, but for future trials in ulcerative colitis, asthma and other indications,” commented Tony Fiorino, MD, PhD, Chief Medical and Operating Officer of Immune. “We are pleased to be working with WuXi Biologics on the scale-up and production of bertilimumab, given its extensive experience in the manufacture of monoclonal antibodies and its vast production capacity. We believe WuXi Biologics is well-positioned to meet foreseeable bertilimumab production demand. We have hit the ground running with WuXi Biologics and have already begun working on the technology transfer.”